Affiliation:
1. School of Pharmaceutical sciences, Geneva University, Geneva, Switzerland
Abstract
Background:
Ticagrelor is a highly recommended new antiplatelet agent for the treatment
of patients with acute coronary syndrome at moderate or high ischemic risk. There is a real need for
rapid and accurate analytical methods for ticagrelor determination in biological fluids for pharmacokinetic
studies. In this study, a sensitive and specific LC-MS method was developed and validated
for quantification of ticagrelor and its Active Metabolite (AM) in human plasma over expected clinical
concentrations.
Methods:
Samples were handled by Liquid-Liquid Extraction (LLE). A linear gradient was applied
with a mobile phase composed of formic acid 0.1% and acetonitrile with 0.1% of formic acid using a
C18 reversed-phase column. MS spectra were obtained by electrospray ionization in negative mode
and optimized at 521.4→360.9 m/z, 477.2→361.2 m/z and 528.1→367.9 m/z transitions for ticagrelor,
AM and ticagrelor-d7, respectively.
Results:
This method allowed rapid elution, in less than 4 minutes, and quantification of concentrations
as low as 2 ng/mL for ticagrelor and 1 ng/mL for AM using only 100 μL of human plasma.
LLE using hexane/ethyl acetate (50/50) was an optimal compromise in terms of extraction recovery
and endogenous compounds interference. Trueness values of 87.8% and 89.5% and precisions of
84.1% and 93.8% were obtained for ticagrelor and AM, respectively. Finally, the usefulness of the
method was assessed in a clinical trial where a single 180 mg ticagrelor was orally administered to
healthy male volunteers. Pharmacokinetic parameters of ticagrelor and its active metabolite were
successfully determined.
Conclusion:
A sensitive and specific quantification LC-MS-MS method was developed and validated
for ticagrelor and its active metabolite determination in human plasma. The method was successfully
applied to a clinical trial where a single ticagrelor 180 mg dose was orally administered to
healthy male volunteers. The described method allows quantification of concentrations as low as 2
ng/mL of ticagrelor and 1 ng/mL of the metabolite using only 100 μL of plasma.
Funder
Swiss National Science Foundation
Publisher
Bentham Science Publishers Ltd.
Reference16 articles.
1. Roffi M.; Patrono C.; Collet J.P.; Mueller C.; Valgimigli M.; Andreotti F.; Bax J.J.; Borger M.A.; Brotons C.; Chew D.P.; ESC Guidelines for the management of acute coronary syndromes
in patients presenting without persistent ST-segment elevation:
Task Force for the Management of Acute Coronary Syndromes in
Patients Presenting without Persistent ST-Segment Elevation of the
European Society of Cardiology (ESC). Eur Heart J 2015,2015
2. Steg P.G.; James S.K.; Atar D.; Badano L.P.; Blömstrom-Lundqvist C.; Borger M.A.; Di Mario C.; Dickstein K.; Ducrocq G.; Fernandez-Aviles F.; Gershlick A.H.; Giannuzzi P.; Halvorsen S.; Huber K.; Juni P.; Kastrati A.; Knuuti J.; Lenzen M.J.; Mahaffey K.W.; Valgimigli M.; van ’t Hof A.; Widimsky P.; Zahger D.; Task Force on the management of ST-segment elevation
acute myocardial infarction of the European Society of Cardiology
(ESC). ESC Guidelines for the management of acute myocardial
infarction in patients presenting with ST-segment elevation Eur Heart J 2012,33(20),2569-2619
3. Serebruany V.L.; Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? Am Heart J 2011,161(1),1-4
4. Teng R.; Oliver S.; Hayes M.A.; Butler K.; Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010,38(9),1514-1521
5. Zhou D.; Andersson T.B.; Grimm S.W.;
In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 2011,39(4),703-710
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献